Large granular lymphocyte leukemia: natural history and response to treatment.
AuthorsFortune, Anne F
Crotty, Gerard M
AffiliationNational Adult Bone Marrow Transplant and Haematology Unit, St James Hospital,, Dublin 8, Ireland. firstname.lastname@example.org
Antibodies, Monoclonal/administration & dosage
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm/administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Drug Therapy, Combination
Immunosuppressive Agents/*therapeutic use
Leukemia, Large Granular Lymphocytic/*drug therapy/pathology
Methotrexate/administration & dosage
Pentostatin/administration & dosage
MetadataShow full item record
CitationLeuk Lymphoma. 2010 May;51(5):839-45.
JournalLeukemia & lymphoma
AbstractLarge granular lymphocyte leukemia (T-LGL) is an indolent T lymphoproliferative disorder that was difficult to diagnose with certainty until clonality testing of the T cell receptor gene became routinely available. We studied the natural history and response to treatment in 25 consecutive patients with T-LGL diagnosed between 2004 and 2008 in which the diagnosis was confirmed by molecular analysis, to define an effective treatment algorithm. The median age at diagnosis was 61 years (range 27-78), with a male to female ratio of 1:1.8 and presenting features of fatigue (n = 13), recurrent infections (n = 9), and/or abnormal blood counts (n = 5). Thirteen patients with symptomatic disease were treated as follows: pentostatin (nine patients), cyclosporine (six patients), methotrexate (three patients), and alemtuzumab in two patients in whom pentostatin was ineffective. Pentostatin was the single most effective therapy, with a response rate of 75% and minimal toxicity. The overall survival (OS) and progression-free survival (PFS) 37 months from diagnosis were 80% and 52%, respectively. Treatment of T-LGL should be reserved for patients with symptomatic disease, but in this series, pentostatin treatment was less toxic and more effective than cyclosporine or methotrexate.
- Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
- Authors: Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H
- Issue date: 2009 Nov 10
- T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years.
- Authors: Aribi A, Huh Y, Keating M, O'brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F
- Issue date: 2007 Jul
- Large granular lymphocytic leukemia: a treatable form of refractory celiac disease.
- Authors: Malamut G, Meresse B, Verkarre V, Kaltenbach S, Montcuquet N, Duong Van Huyen JP, Callens C, Lenglet J, Rahmi G, Samaha E, Ranque B, Macintyre E, Radford-Weiss I, Hermine O, Cerf-Bensussan N, Cellier C
- Issue date: 2012 Dec
- T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature.
- Authors: Osuji N, Matutes E, Tjonnfjord G, Grech H, Del Giudice I, Wotherspoon A, Swansbury JG, Catovsky D
- Issue date: 2006 Aug 1
- Complete response in a patient with adult T-cell leukemia (ATL) treated with combination of alemtuzumab and pentostatin.
- Authors: Ravandi F, Faderl S
- Issue date: 2006 Jan